Search

Your search keyword '"Ramnath, Nithya"' showing total 583 results
Start Over Author "Ramnath, Nithya"
583 results on '"Ramnath, Nithya"'

151. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer

Author

He, Yanli, primary, Wang, Lihui, additional, Liu, Weijun, additional, Zhong, Jinjie, additional, Bai, Shengbin, additional, Wang, Zhuwen, additional, Thomas, Dafydd G., additional, Lin, Jules, additional, Reddy, Rishindra M., additional, Ramnath, Nithya, additional, Carrott, Philip W., additional, Lynch, William R., additional, Orringer, Mark B., additional, Chang, Andrew C., additional, Beer, David G., additional, and Chen, Guoan, additional

Published
2015
Full Text
View/download PDF

152. Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.

Author

Cobain, Erin Frances, primary, Robinson, Dan R., additional, Wu, Yi-Mi, additional, Worden, Francis P., additional, Smith, David C., additional, Schuetze, Scott, additional, Chugh, Rashmi, additional, Ramnath, Nithya, additional, Schott, Anne F., additional, Hayes, Daniel F., additional, Chinnaiyan, Arul M., additional, and Talpaz, Moshe, additional

Published
2015
Full Text
View/download PDF

153. A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Author

Miller, Antonius A., Pang, Herbert, Hodgson, Lydia, Ramnath, Nithya, Otterson, Gregory A., Kelley, Michael J., Kratzke, Robert A., and Vokes, Everett E.

Subjects
Adult, Aged, 80 and over, Male, Salvage Therapy, Lung Neoplasms, Dasatinib, Antineoplastic Agents, Middle Aged, Small Cell Lung Carcinoma, Article, Survival Rate, Thiazoles, Young Adult, Pyrimidines, Treatment Outcome, Drug Resistance, Neoplasm, Humans, Female, Neoplasm Recurrence, Local, Protein Kinase Inhibitors, Aged, Neoplasm Staging
Abstract

SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progressionor =90 days after completing first-line therapy) small cell lung cancer.Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible. Dasatinib was administered orally at 70 mg twice daily continuously (1 cycle = 21 days) until disease progression or unacceptable toxicity. Response was determined after every two cycles. Patients were followed until disease progression or death. The study was prospectively designed to simultaneously discriminate between complete plus partial response rates of 5% versus 20% and progression-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable patients with at least 92% power. The study was to be terminated early and declared negative if 1 or less objective response and 14 or fewer instances of PFSor =6 weeks were observed among the initial 27 patients; however, patient accrual continued while the initial 27 patients were evaluated.Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31. No objective response was recorded among the 43 eligible and treated patients. Among the initial 27 patients, only 13 instances of PFSor =6 weeks were observed. With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively. Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%). Toxicity was generally mild to moderate: grade 3 events of5% frequency included fatigue and pleural and pericardial effusions; and no grade 4 or 5 events were encountered.Dasatinib did not reach our specified efficacy criteria in this clinical setting, and the study was terminated.

Published
2010

154. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Author

Feng-Ming Kong, Ten Haken, Randall K., Schipper, Matthew, Frey, Kirk A., Hayman, James, Gross, Milton, Ramnath, Nithya, Hassan, Khaled A., Matuszak, Martha, Ritter, Timothy, Nan Bi, Wang, Weili, Orringer, Mark, Cease, Kemp B., Lawrence, Theodore S., and Kalemkerian, Gregory P.

Published
2017
Full Text
View/download PDF

158. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model

Author

Zhang, Zhuo, primary, Shiratsuchi, Hiroe, additional, Lin, Jules, additional, Chen, Guoan, additional, Reddy, Rishindra M., additional, Azizi, Ebrahim, additional, Fouladdel, Shamileh, additional, Chang, Andrew C., additional, Lin, Lin, additional, Jiang, Hui, additional, Waghray, Meghna, additional, Luker, Gary, additional, Simeone, Diane M., additional, Wicha, Max S., additional, Beer, David G., additional, Ramnath, Nithya, additional, and Nagrath, Sunitha, additional

Published
2014
Full Text
View/download PDF

159. Abstract 3075: Ex-vivo expansion of circulating tumor cells in early lung cancer using a microfluidic model

Author

Zhang, Jennifer Zhuo, primary, Shiratsuchi, Hiroe, additional, Lin, Jules, additional, Chen, Guoan, additional, Reddy, Rishindra M., additional, Azizi, Ebrahim, additional, Fouladdel, Shamileh, additional, Chang, Andrew C., additional, Lin, Lin, additional, Simeone, Diane M., additional, Wicha, Max S., additional, Beer, David G., additional, Ramnath, Nithya, additional, and Nagrath, Sunitha, additional

Published
2014
Full Text
View/download PDF

167. A phase II trial of mid-treatment FDG-PET adaptive, individualized radiation therapy plus concurrent chemotherapy in patients with non-small cell lung cancer (NSCLC).

Author

Kong, Fengming, primary, Ten Haken, Randall K, additional, Schipper, Matthew J, additional, Hayman, James, additional, Ramnath, Nithya, additional, Hassan, Khaled Aref, additional, Matuszak, Martha, additional, Ritter, Timothy, additional, Bi, Nan, additional, Wang, Weili, additional, Orringer, Mark, additional, Cease, Kemp Bailey, additional, Lawrence, Theodore Steven, additional, and Kalemkerian, Gregory Peter, additional

Published
2013
Full Text
View/download PDF

169. An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (S56.002)

Author

Nayak, Lakshmi, primary, Abrey, Lauren, additional, DeAngelis, Lisa, additional, Gadgeel, Shirish, additional, Garst, Jennifer, additional, Govindan, Ramaswamy, additional, Kelly, Karen, additional, Omuro, Antonio, additional, Peereboom, David, additional, Ramnath, Nithya, additional, Reimers, Hans-Joachim, additional, Rigas, James, additional, Robbins, H. Ian, additional, Rosenfeld, Steven, additional, and Wen, Patrick, additional

Published
2013
Full Text
View/download PDF

170. An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC) (IN10-2.005)

Author

Nayak, Lakshmi, primary, Abrey, Lauren, additional, DeAngelis, Lisa, additional, Gadgeel, Shirish, additional, Garst, Jennifer, additional, Govindan, Ramaswamy, additional, Kelly, Karen, additional, Omuro, Antonio, additional, Peereboom, David, additional, Ramnath, Nithya, additional, Reimers, Hans-Joachim, additional, Rigas, James, additional, Robbins, H. Ian, additional, Rosenfeld, Steven, additional, and Wen, Patrick, additional

Published
2013
Full Text
View/download PDF

172. Pulmonary venous blood sampling significantly increases the yield of circulating tumor cells in early-stage lung cancer.

Author

Reddy, Rishindra M., Murlidhar, Vasudha, Zhao, Lili, Grabauskiene, Svetlana, Zhang, Zhuo, Ramnath, Nithya, Lin, Jules, Chang, Andrew C., Carrott, Phillip, Lynch, William, Orringer, Mark B., Beer, David G., and Nagrath, Sunitha

Abstract

Objective To identify circulating tumor cells (CTCs) in the blood of patients with early-stage lung cancer and to show that sampling pulmonary vein (PV) blood using microfluidic chip technology will yield significantly more CTCs. Improving early detection of lung cancer is critical to improving lung cancer survival. Reproducible detection of CTCs is limited currently in early stage tumors. Methods Patients undergoing pulmonary resection had PV blood drawn before resection. Peripheral blood was sampled at preoperative, intraoperative, and postoperative times. Samples were analyzed on microfluidic chips using antibody-based capture. Results A total of 32 patients with primary lung cancer were evaluated. Twenty patients had 1 or more CTCs detected in at least 1 sample (62.5%). The mean number of CTCs from peripheral vein sources at the preoperative, intraoperative, and postoperative time points was 1.3, 1.9, and 0.6 respectively. The average number of CTCs in the PV was 340.0 (range, 0.0-5422.50; P > .01). When PV CTCs were present, the number of CTCs was correlated with pathological tumor size ( P = .0236). The number of PV CTCs was not correlated with any other clinical feature (eg, smoking status, preoperative or postoperative stage). Furthermore, the number of PV CTCs was significantly higher when preoperative bronchoscopic biopsy was performed, compared with computed tomography–guided biopsy ( P = .0311). Seven patients had evidence of CTC clusters, or microemboli. Conclusions With a single vein draining the entire tumor basin, lung cancers are unique, allowing the high-yield isolation of CTCs from the PV. This method may facilitate future studies to improve the detection and analysis of early-stage lung CTCs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

173. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma

Author

Kim, So Hee, primary, Chen, Guoan, additional, King, Amanda N., additional, Jeon, Chae Kyung, additional, Christensen, Paul J., additional, Zhao, Lili, additional, Simpson, Robert U., additional, Thomas, Dafydd G., additional, Giordano, Thomas J., additional, Brenner, Dean E., additional, Hollis, Bruce, additional, Beer, David G., additional, and Ramnath, Nithya, additional

Published
2012
Full Text
View/download PDF

174. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer.

Author

Ramnath, Nithya, primary, Daignault-Newton, Stephanie, additional, Dy, Grace K., additional, Muindi, Josephia, additional, Adjei, Araba, additional, Kalemkerian, Gregory Peter, additional, Cease, Kemp Bailey, additional, Stella, Philip J., additional, Brenner, Dean E., additional, Johnson, Candace S., additional, and Trump, Donald L., additional

Published
2012
Full Text
View/download PDF

176. Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).

Author

Farooq, Aamer, primary, Dy, Grace K., additional, Demmy, Todd L., additional, Bogner, Paul, additional, Nowadly, Cynthia, additional, Tan, Wei, additional, Chen, Hongbin, additional, Yendamuri, Saikrishna S., additional, Nwogu, Chukwumere E., additional, Bushunow, Peter Walter, additional, Adjei, Alex A., additional, and Ramnath, Nithya, additional

Published
2012
Full Text
View/download PDF

178. Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer

Author

Yuan, Shuanghu (Tiger), primary, Frey, Kirk A., additional, Gross, Milton D., additional, Hayman, James A., additional, Arenberg, Doug, additional, Cai, Xu-Wei, additional, Ramnath, Nithya, additional, Hassan, Khaled, additional, Moran, Jean, additional, Eisbruch, Avraham, additional, Ten Haken, Randall K., additional, and Kong, Feng-Ming (Spring), additional

Published
2012
Full Text
View/download PDF

179. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial

Author

Kong, Feng-Ming, Ten Haken, Randall K., Schipper, Matthew, Frey, Kirk A., Hayman, James, Gross, Milton, Ramnath, Nithya, Hassan, Khaled A., Matuszak, Martha, Ritter, Timothy, Bi, Nan, Wang, Weili, Orringer, Mark, Cease, Kemp B., Lawrence, Theodore S., and Kalemkerian, Gregory P.

Abstract

IMPORTANCE: Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabolic shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment provides an opportunity to deliver higher-dose radiation to the more aggressive areas of the tumor to improve local tumor control without increasing RT-induced lung toxicity (RILT), and possibly improve survival. OBJECTIVE: To determine whether adaptive RT can target high-dose radiation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanced non–small-cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: A phase 2 clinical trial conducted at 2 academic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from November 2008, to May 2012. Patients with poor performance, more than 10% weight loss, poor lung function, and/or oxygen dependence were included, providing that the patients could tolerate the procedures of PET scanning and RT. INTERVENTION: Conformal RT was individualized to a fixed risk of RILT (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions. Medically fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was local tumor control. The trial was designed to achieve a 20% improvement in 2-year control from 34% of our prior clinical trial experience with 63 to 69 Gy in a similar patient population. RESULTS: The trial reached its accrual goal of 42 patients: median age, 63 years (range, 45-83 years); male, 28 (67%); smoker or former smoker, 39 (93%); stage III, 38 (90%). Median tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions. Median follow-up for surviving patients was 47 months. The 2-year rates of infield and overall local regional tumor controls (ie, including isolated nodal failure) were 82% (95% CI, 62%-92%) and 62% (95% CI, 43%-77%), respectively. Median overall survival was 25 months (95% CI, 12-32 months). The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% CI, 16%-45%), respectively. CONCLUSIONS AND RELEVANCE: Adapting RT-escalated radiation dose to the FDG-avid tumor detected by midtreatment PET provided a favorable local-regional tumor control. The RTOG 1106 trial is an ongoing clinical trial to validate this finding in a randomized fashion. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01190527

Published
2017
Full Text
View/download PDF

180. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma

Author

Shiratsuchi, Hiroe, Wang, Zhuwen, Chen, Guoan, Ray, Paramita, Lin, Jules, Zhang, Zhuo, Zhao, Lili, Beer, David, Ray, Dipankar, and Ramnath, Nithya

Abstract

We have previously demonstrated that a subset of lung cancer cells express higher CYP24A1mRNA, a metabolizing enzyme for 1,25-D3, compared to benign tumors or surrounding normal lung and that high CYP24A1mRNA expression is associated with poor prognosis in resected lung adenocarcinoma (AC). We hypothesized that CYP24A1 has oncogenic potential and increased CYP24A1 expression may contribute to tumor growth, whereas, CYP24A1 targeting may reduce tumor burden.

Published
2017
Full Text
View/download PDF

181. Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALKRearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study

Author

Zhang, Zhuo, Shiratsuchi, Hiroe, Palanisamy, Nallasivam, Nagrath, Sunitha, and Ramnath, Nithya

Abstract

The emergence of liquid biopsy using circulating tumor cells (CTCs) as a resource to identify genomic alterations in cancer presents new opportunities for diagnosis, therapy, and surveillance. We identified EML4-ALKgene rearrangement in expanded CTCs from a patient with ALK-positive lung adenocarcinoma. At the time of radiographic progression, CTCs obtained from the patient revealed a drug resistance mutation (i.e., L1196M on the ALKgene). CTCs were expanded ex vivo and drug sensitivity testing was performed using two ALK inhibitors, crizotinib and ceritinib. The half maximal inhibitory concentration of ceritinib was 1664 nM compared with crizotinib (2268 nM), showing that ceritinib was a more potent ALK inhibitor. We show that it is feasible to detect serial genetic alterations in expanded CTCs and perform in vitro drug screening. These findings support the clinical utility of CTCs not only for diagnosis, but also a potential tool for drug sensitivity testing in distinct subsets of lung cancer and for personalized precision medicine.

Published
2017
Full Text
View/download PDF

183. CYP24A1Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma

Author

Chen, Guoan, primary, Kim, So Hee, additional, King, Amanda N., additional, Zhao, Lili, additional, Simpson, Robert U., additional, Christensen, Paul J., additional, Wang, Zhuwen, additional, Thomas, Dafydd G., additional, Giordano, Thomas J., additional, Lin, Lin, additional, Brenner, Dean E., additional, Beer, David G., additional, and Ramnath, Nithya, additional

Published
2011
Full Text
View/download PDF

184. EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation

Author

Faoro, Leonardo, primary, Singleton, Patrick A., additional, Cervantes, Gustavo M., additional, Lennon, Frances E., additional, Choong, Nicholas W., additional, Kanteti, Rajani, additional, Ferguson, Benjamin D., additional, Husain, Aliya N., additional, Tretiakova, Maria S., additional, Ramnath, Nithya, additional, Vokes, Everett E., additional, and Salgia, Ravi, additional

Published
2010
Full Text
View/download PDF

187. Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

Author

Krishnaswamy, Soundararajan, primary, Kanteti, Rajani, additional, Duke-Cohan, Jonathan S., additional, Loganathan, Sivakumar, additional, Liu, Wanqing, additional, Ma, Patrick C., additional, Sattler, Martin, additional, Singleton, Patrick A., additional, Ramnath, Nithya, additional, Innocenti, Federico, additional, Nicolae, Dan L., additional, Ouyang, Zheng, additional, Liang, Jie, additional, Minna, John, additional, Kozloff, Mark F., additional, Ferguson, Mark K., additional, Natarajan, Viswanathan, additional, Wang, Yi-Ching, additional, Garcia, Joe G.N., additional, Vokes, Everett E., additional, and Salgia, Ravi, additional

Published
2009
Full Text
View/download PDF

191. Expression and mutational analysis ofMETin human solid cancers

Author

Ma, Patrick C., primary, Tretiakova, Maria S., additional, MacKinnon, Alexander C., additional, Ramnath, Nithya, additional, Johnson, Candace, additional, Dietrich, Sascha, additional, Seiwert, Tanguy, additional, Christensen, James G., additional, Jagadeeswaran, Ramasamy, additional, Krausz, Thomas, additional, Vokes, Everett E., additional, Husain, Aliya N., additional, and Salgia, Ravi, additional

Published
2008
Full Text
View/download PDF

199. Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

Author

Vokes, Everett E., primary, Herndon, James E., additional, Kelley, Michael J., additional, Cicchetti, M. Giulia, additional, Ramnath, Nithya, additional, Neill, Harvey, additional, Atkins, James N., additional, Watson, Dorothy M., additional, Akerley, Wallace, additional, and Green, Mark R., additional

Published
2007
Full Text
View/download PDF

200. Current status of CTCs as liquid biopsy in lung cancer and future directions.

Author

Zhuo Zhang, Ramnath, Nithya, Nagrath, Sunitha, Chen, Yuhchyau, Deepak, Janaki, and Pennell, Nathan A.

Subjects
CANCER cells, BIOPSY, LUNG cancer
Abstract

Circulating tumor cells (CTCs) have garnered a lot of attention in the past few decades. Isolation of these rare cells from the billions of blood cells has been a challenge until recent times. With the advent of new sensitive technologies that permit live cell isolation and downstream genomic analysis, the existing paradigm of CTC research has evolved to explore clinical utility of these cells. CTCs have been identified as prognostic and pharmacodynamic biomarkers in many solid tumors, including lung cancer. As a means of liquid biopsy, CTCs could play a major role in the development of personalized medicine and targeted therapies. This review discusses the state of various isolation strategies, cell separation techniques and key studies that illustrate the application of liquid biopsy to lung cancer. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results